A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.

Matthias KloorMiriam ReuschenbachClaudia PauligkJulia KarbachMohammad-Reza RafiyanSalah-Eddin Al-BatranMirjam TariverdianElke JägerMagnus von Knebel-Doeberitz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

FSP neoantigen vaccination is systemically well tolerated and consistently induces humoral and cellular immune responses, thus representing a promising novel approach for treatment and even prevention of MMR-deficient cancer.

Keyphrases

immune response
clinical trial
papillary thyroid
toll like receptor
open label
study protocol
childhood cancer
double blind
randomized controlled trial
wild type
lymph node metastasis